for businesses
With expansion a prime focus for businesses
worldwide, many are looking
EUROPE & MIDDLE EAST by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
towards rapidly establishing new regions of growth, particularly in Europe and the Middle East.
Dundee to Provide Data Reception and Processing for Indian Satellite
from space, to install and test acquisition and generation systems and train DSRS engineers on operations to receive data.
The primary purpose of this collaboration is to collect and distribute these data to UK environmental scientists to support marine science research. More broadly, DSRS data are also used in areas such as meteorology and vegetation, snow/ice, volcano and earthquake research.
Dr Paul Crawford, DSRS and Sailaja Poduri, ISRO.
The University of Dundee has entered into an agreement with Antrix Corporation Limited, the commercial arm of the Indian Space Research Organisation (ISRO), to receive data from one of its Oceansat-2 Earth Observation (EO) satellite.
Engineers from Antrix/ISRO have visited the Dundee Satellite Receiving Station (DSRS), one of the UK’s main facilities for acquiring data
Historically, data received at Dundee have been provided by US and European satellites. The agreement with Antrix provides an opportunity to broaden the range of satellite data available to users and develop a new partnership with ISRO, another major satellite operator. DSRS will be only the second ground station outside India to receive Oceansat-2 data directly.
Dr Paul Crawford, of the DSRS, said, “We are delighted to be working with the Indian Space Research Organisation, who have made signifi cant advances in the fi eld in recent years.
The data from this EO satellite are received and processed by their National Remote Sensing Centre near Hyderabad.
“At present, we will be one of only two sites outside of the Indian coverage area to receive and process the ocean colour image data directly and as such it will be a very useful addition to the other satellites we routinely take data from. Both sides look forward to continued cooperation for future satellite missions.”
DSRS works with Plymouth Marine Laboratory in operating the NERC Earth Observation Data Acquisition and Analysis Service (NEODAAS), which is funded by the National Centre for Earth Observation. NEODAAS provides real time and historic information generated from EO satellite data, such as chlorophyll levels and sea surface temperatures for marine scientists.
39921pr@reply-direct.com
Agreement Brings Therapeutic Antibody into Manufacture Clinical stage biopharmaceutical company
offering to Phase I and II clinical studies.
Faron Pharmaceuticals Ltd has formed an agreement with Abzena plc, for the manufacture of Clevegen®
, a therapeutic
antibody developed by Faron to reduce immune suppression in cancer. Clevegen may also have the potential to be used in other situations where there is an inadequate immune response, such as in chronic infections or during vaccination, the company said.
Clevegen was humanised by Abzena using its Composite Human Antibody®
technology.
Under the agreement with Faron, Abzena will produce the Master Cell Bank and manufacture the antibody for clinical development under cGMP conditions. This is the fi rst product produced using Abzena’s humanisation technology that will also be manufactured by Abzena following its acquisition of Pacifi cGMP in San Diego, USA, in September 2015 to expand its manufacturing
Faron had previously signed an agreement with Selexis to obtain cell clones with high Clevegen production. This collaboration has progressed as planned and the best selected clone will be used by Abzena to produce the Master Cell Bank for Faron.
Markku Jalkanen, CEO of Faron Pharmaceuticals said: “We are very happy to collaborate with Abzena for GMP production of Clevegen to complete our pre-clinical development, and subsequently enter the clinic. We believe that Clevegen can bring an exciting new immune check point target to cancer therapies as it drives conversion of immune suppressive type 2 macrophages to immune active type 1 macrophages.”
John Burt, CEO of Abzena commented: “We are pleased to have this opportunity to enable Faron to progress this Abzena Inside antibody
John Burt Markku Jalkanen
towards clinical development through this manufacturing agreement. Following the expansion of our business into the US last year, we have the ability to facilitate our partners’ journeys from antibody humanisation to clinical trials.”
39904pr@reply-direct.com
Business
Opportunities
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132
